Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

290 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-19

Study Completion Date

2023-07-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to collect clinical, biological and quality of life data from patients with a borderline or resectable pancreatic cancer. It will collect information from the date of diagnosis along the therapeutic care of the patients, and a 3-years follow-up after the end of the treatment. The database will be updated at each patient's visit. Biological samples will include: tumor, and plasma. Epidemiological data will also be collected, whereas Quality of life will be assessed by the EORTC standard. The objectives of this database are to identify new biomarkers (genomic, immunologic, and epidemiologic) and promote high quality standard research protocol.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multi-omics Characterization of Pancreatic Neuroendocrine Tumors and Carcinomas

NCT05234450

Cancer of Pancreas

UNKNOWN

PAncreas Borderline and Locally Advanced Snapshot Study

NCT05470738

Pancreatic Cancer

UNKNOWN

Pancreatic Adenocarcinoma Gene Environment Risk Study

NCT00912717

Pancreatic Cancer

RECRUITING

Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors

NCT01692873

Pancreatic Tumor

COMPLETED NA

Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer

NCT05356039

Pancreas Cancer Pancreas Neoplasm Pancreas Disease +6 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Additional biological samples

Additional blood samples will be realized specifically to the study at baseline, after neoadjuvant chemotherapy (if applicable) and before surgery, 1 month after surgery and 1 month after the last adjuvant chemotherapy cycle.

Peripheral blood mononuclear cell (PBMC), plasma and circulating tumor DNA and RNA will be collected.

Tumor tissue will be collected during surgery.

Group Type OTHER

Additional biological samples

Intervention Type OTHER

blood and tumor tissue samples

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Additional biological samples

blood and tumor tissue samples

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with exocrine resectable pancreatic adenocarcinoma or potentially resectable (that after neoadjuvant treatment are considered appropriate candidates for resection)
* Histologically or cytologically documented diagnosis of exocrine pancreatic adenocarcinoma
* Written informed consent obtained prior enrollment in the study

Exclusion Criteria

* other types of pancreatic cancer, in particular endocrine tumor or acinar cells
* ampulloma
* metastatic disease
* other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer
* patient with any medical or psychiatric condition or disease which would make the patient inappropriate for entry into this study
* patient under guardianship, curator or under the protection of justice.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No